Skip to main content

Advertisement

Table 3 Univariate and multivariate analyses of the prognostic factors on overall survival after lymph node recurrence

From: The outcome and prognostic factors for lymph node recurrence after node-sparing definitive external beam radiotherapy for localized prostate cancer

  2-year survival rate (%) p value HR (95 % CI) p value
Age
 ≥70 41 0.160   
v<70 80    
T stage
 T3–T4 37 0.236   
 T1–T2 100    
Gleason score
 8–10 47 0.661   
 ≤7 63    
PSA (ng/ml)
 ≥20 50 0.762   
 <20 58    
Isolated lymph node recurrence
 Yes 67 0.003 5.22 (0.50–55.03) 0.169
 No 0    
PSA doubling time
 >5 months 89 0.009 1.869 (0.05–74.19) 0.739
 <5 months 17    
PSA nadir-free interval
 >12 months 80 0.035 1.203 (0.09–15.62) 0.888
 <12 months 20    
PSA at lymph node recurrence (ng/ml)
 >10 19 0.003 510,993 (0–1.22E184) 0.950
 <10 100    
  1. ADT Androgen deprivation therapy, HR hazard ratio, CI confidence interval